ArticleFrontiers in pharmacology2026
LP533401 treatment alters vitamin K metabolism, bone Gla-OC/Glu-OC ratios, and improves mineral status of the skeleton in rats with chronic kidney disease.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic kidney disease-mineral and bone disorder (CKD-MBD) is associated with impaired bone mineralization and vitamin K (VK) deficiency. Peripheral serotonin (5-HT) adversely affects bone integrity, but its relationship with VK metabolism remains unknown. In this study, we investigated the effects of LP533401 (LP), a small molecule inhibitor of peripheral 5-HT synthesis in the gut, on VK metabolism, VK-dependent proteins (VKDPs), and mineral status of the skeleton in CKD rats. Methods: Serum levels of phylloquinone (VK1), menaquinone 4 and 7 (MK4, MK7), serum and bone VKDPs concentrations, bone VK cycle genes expression, and mineral status of the skeleton were determined in CKD rats treated with vehicle or LP at the dose of 30 or 100 mg/kg daily. Results: LP treatment altered VK metabolism by restoring circulating VK1 levels and promoting MK7 over MK4 synthesis. At the molecular level, LP treatment modulated the expression of VK cycle genes ( Conclusion: LP treatment modulates VK metabolism, VKDPs levels in bone and serum, and improves bone mineralization in the rat CKD model. This study provides a new perspective on the therapeutic potential targeting the modulation of peripheral serotonin and VK-dependent signaling to improve bone mineralization, which is impaired in CKD-MBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.